Overview: DRVVT Screen TestIntroduction: The DRVVT Screen Test screens for lupus anticoagulant to diagnose antiphospholipid syndrome, helping identify risks for blood clots or pregnancy complications. Affecting 1 in 2,000 people, antiphospholipid syndrome poses diagnostic challenges due to variable presentation. Following 2023 International Society on Thrombosis and Haemostasis (ISTH) guidelines, it uses coagulation assay for high sensitivity, supporting coagulation screening. This test is essential for initial diagnosis, risk assessment, and improving outcomes in hematology.
Other Names: Lupus Anticoagulant Screening Test, DRVVT Initial Assay.
FDA Status: Laboratory-developed test (LDT), meeting coagulation standards for diagnostic reliability.
Historical Milestone: Anticoagulant testing began in the 1980s with research by Exner, who developed DRVVT. Assay refinements in the 2000s by Siemens improved detection, surpassing earlier mixing studies.
Purpose: Screens for lupus anticoagulant to identify antiphospholipid syndrome, guides further testing, and evaluates patients with clots, aiming to prevent recurrence.
Test Parameters: DRVVT screening result
Pretest Condition: No special preparation required. Collect plasma. Report history of clotting issues.
Specimen: Plasma (NaCit, 2-4 mL); 2 mL plasma in Na Citrate tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: 1 month
Medical History: Document blood clots or pregnancy issues. Include current medications or anticoagulant use.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., stroke), and sample collection risks.
Procedural Considerations: Uses coagulation assay to screen DRVVT, requiring labs with coagulometers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Anticoagulants may alter results, requiring correlation.
Clinical Significance: Positive screen indicates potential syndrome, guiding confirmation. Early detection might prevent clots, while negative results may require repeat testing. Results need confirmation.
Specialist Consultation: Consult a hematologist for interpretation.
Additional Supporting Tests: Anticardiolipin antibody, beta-2 glycoprotein, or ultrasound to confirm diagnosis.
Test Limitations: Non-specific; correlation with symptoms needed. False positives possible with other conditions.
References: ISTH Guidelines, 2023; Thrombosis and Haemostasis, Exner T, 2022.
